Aligos Therapeutics, Inc.

ALGS

Healthcare|Biotechnology|US

$4.07

-0.44 (-9.76%)

DCF Value

$0.13

Tangible Book / Share

$1.08

Cash / Share

$2.97

Clinical Trials (15)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06963710 A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)	Chronic Hepatitis B Infection	P2	Active	200	RCT, Double-blind	ALG-000184, TDF
NCT06672900 A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers	Healthy Volunteer	P1	Active	24	Open-label	Carbamazepine, Itraconazole (Sporanox), ALG-000184
NCT06342947 ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)	NASH, MASH	P2	Completed	102	RCT, Double-blind	ALG-055009, Placebo
NCT06568861 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function	COVID-19	P1	Completed	16	Open-label	ALG-097558
NCT05840952 A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558	COVID-19	P1	Completed	90	RCT, Double-blind	ALG-097558, Placebo, Midazolam, Itraconazole, Carbamazepine, ALG-097558 in solution formulation, ALG-097558 in tablet formulation
NCT05090111 A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia	NASH - Nonalcoholic Steatohepatitis	P1	Completed	98	RCT, Double-blind	ALG-055009, Placebo
NCT04536337 A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects	Chronic Hepatitis B	P1	Completed	165	RCT, Double-blind	ALG-000184, Placebo, Entecavir
NCT07342881 Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function	Chronic Hepatitis B Infection	P1	Completed	12	Open-label	Pevifoscorvir Sodium (ALG-000184)
NCT07342868 Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function	Chronic Hepatitis B Infections	P1	Completed	20	Open-label	Pevifoscorvir Sodium (ALG-000184)
NCT04485663 A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects	Chronic Hepatitis B	P1	Terminated	103	RCT, Double-blind	ALG-010133, Placebo
NCT05561530 A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects	Chronic Hepatitis B	P1	Terminated	57	RCT, Double-blind	ALG-125755, Placebo
NCT06959888 A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations	Healthy Volunteer Study	P1	Completed	8	RCT, Open-label	ALG-055009
NCT05001022 A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects	Chronic Hepatitis B	P1	Terminated	40	RCT, Double-blind	ALG-020572, Placebo
NCT06698549 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function	COVID 19	P1	Completed	12	Open-label	ALG-097558
NCT06191991 A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)	Healthy Volunteers	P1	Completed	14	Open-label	Atorvastatin, ALG-055009, Rosuvastatin